| dc.contributor.author | O'SULLIVAN, JACINTHA | |
| dc.date.accessioned | 2015-03-11T12:45:09Z | |
| dc.date.available | 2015-03-11T12:45:09Z | |
| dc.date.issued | 2012 | |
| dc.date.submitted | 2012 | en |
| dc.identifier.citation | Michielsen AJ, Ryan EJ, O'Sullivan JN, Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment., Oncoimmunology, 1, 8, 2012, 1445-1447 | en |
| dc.identifier.other | Y | |
| dc.identifier.uri | http://hdl.handle.net/2262/73550 | |
| dc.description | PUBLISHED | en |
| dc.description.abstract | we demonstrated that dendritic cell (DC) inhibition by tumor-conditioned media in the presence or absence of
bevacizumab correlates with colorectal cancer patient survival. Monitoring the influence of the tumor microenvironment
on infiltrating immune cells may offer an avenue for the discovery of biomarkers to guide the use of bevacizumab | en |
| dc.format.extent | 1445-1447 | en |
| dc.language.iso | en | en |
| dc.relation.ispartofseries | Oncoimmunology; | |
| dc.relation.ispartofseries | 1; | |
| dc.relation.ispartofseries | 8; | |
| dc.rights | Y | en |
| dc.subject | tumor microenvironment | en |
| dc.subject | dendritic cells | en |
| dc.subject | colorectal cancer | en |
| dc.subject | bevacizumab | en |
| dc.title | Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment. | en |
| dc.type | Journal Article | en |
| dc.type.supercollection | scholarly_publications | en |
| dc.type.supercollection | refereed_publications | en |
| dc.identifier.peoplefinderurl | http://people.tcd.ie/osullij4 | |
| dc.identifier.rssinternalid | 83332 | |
| dc.rights.ecaccessrights | openAccess | |
| dc.identifier.rssuri | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518533/pdf/onci-1-1445.pdf | en |
